ARN2966
(Synonyms: 2-PMAP) 目录号 : GC11309
An inhibitor of APP production and Aβ secretion
Cas No.:102212-26-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
ARN2966 is a potent post-transcriptional modulator of amyloid precursor protein (APP) expression in transfected CHO cells. The CHO cell can produce APP.[1]
APP is the amyloid precursor protein of Alzheimer’s disease. Alzheimer’s disease is a progressive dementia with the symptoms of neuronal degeneration, synaptic loss, and the deposition of amyloid fibrils in the brain. Ab protein is the major constituent of the amyloid . Then the Ab protein derives from the amyloid precursor protein (APP). It has been proved that APP can stimulate neurite outgrowth in vitro. [2]
The modulation of App expression of the ARN2966 functions as a post-transcriptional modulation,which is different from other mechanisms such as inhibition of secretases. ARN2966 showed dose dependant inhibition of Aß40 and Aß42 productions in APP751SW transfected CHO cells (IC50
There has been AD transgenic mice model proved ARN2966’s efficacy and tolerability in vivo. Through the treatment of ARN2966, the memory of mice has been improved and A load in the brain has been reduced.
References:
[1] Ayodeji Asuni ,Xu Kevin , etal. , An APP translation modulator ARN2966 reduces BETA-AMYLOID deposition and prevents memory deficits in ALZHEIMER'S DISEASE transgenic mice. Alzheimer's & Dementia: The Journal of the Alzheimer's Association, July 2012Volume 8, Issue 4, Supplement, Page S744 ;
[2]Williamson TG1, Mok SS, Henry A, etal. , Secreted glypican binds to the amyloid precursor protein of Alzheimer's disease (APP) and inhibits APP-induced neurite outgrowth. J Biol Chem. 1996 Dec 6;271(49):31215-21.
| Cas No. | 102212-26-0 | SDF | |
| 别名 | 2-PMAP | ||
| 化学名 | 2-((pyridin-2-ylmethyl)amino)phenol | ||
| Canonical SMILES | OC1=CC=CC=C1NCC2=NC=CC=C2 | ||
| 分子式 | C12H12N2O | 分子量 | 200.24 |
| 溶解度 | DMSO: ≥ 43.4 mg/mL | 储存条件 | Desiccate at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.994 mL | 24.97 mL | 49.9401 mL |
| 5 mM | 0.9988 mL | 4.994 mL | 9.988 mL |
| 10 mM | 0.4994 mL | 2.497 mL | 4.994 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。